Synthesis, structural activity-relationships, and biological evaluation of novel amide-based allosteric binding site antagonists in NR1A/NR2B N-methyl-D-aspartate receptors.

Cara A Mosley, Scott J Myers, Ernest E Murray, Rose Santangelo, Yesim A Tahirovic, Natalie Kurtkaya, Praseeda Mullasseril, Hongjie Yuan, Polina Lyuboslavsky, Phuong Le, Lawrence J Wilson, Manuel Yepes, Ray Dingledine, Stephen F Traynelis, Dennis C Liotta

Index: Bioorg. Med. Chem. 17(17) , 6463-80, (2009)

Full Text: HTML

Abstract

The synthesis and structure-activity relationship analysis of a novel class of amide-based biaryl NR2B-selective NMDA receptor antagonists are presented. Some of the studied compounds are potent, selective, non-competitive, and voltage-independent antagonists of NR2B-containing NMDA receptors. Like the founding member of this class of antagonists (ifenprodil), several interesting compounds of the series bind to the amino terminal domain of the NR2B subunit to inhibit function. Analogue potency is modulated by linker length, flexibility, and hydrogen bonding opportunities. However, unlike previously described classes of NR2B-selective NMDA antagonists that exhibit off-target activity at a variety of monoamine receptors, the compounds described herein show much diminished effects against the hERG channel and alpha(1)-adrenergic receptors. Selections of the compounds discussed have acceptable half-lives in vivo and are predicted to permeate the blood-brain barrier. These data together suggest that masking charged atoms on the linker region of NR2B-selective antagonists can decrease undesirable side effects while still maintaining on-target potency.